Radiosensitivity of Colon and Rectal Lung Oligometastasis Treated With Stereotactic Ablative Radiotherapy

[1]  L. Uhlmann,et al.  Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". , 2016, Lung cancer.

[2]  Elisabetta Cagni,et al.  Lung stereotactic ablative body radiotherapy: A large scale multi-institutional planning comparison for interpreting results of multi-institutional studies. , 2016, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

[3]  Oliver Blanck,et al.  Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  Joon-Oh Park,et al.  The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis , 2016, BMC Cancer.

[5]  Jong Hoon Kim,et al.  Clinical efficacy of stereotactic ablative radiotherapy for lung metastases arising from colorectal cancer , 2015, Radiation oncology.

[6]  Deepinder P. Singh,et al.  Stereotactic Body Radiotherapy for Lung Metastases from Colorectal Cancer: Prognostic Factors for Disease Control and Survival , 2015, American journal of clinical oncology.

[7]  B. Loo,et al.  Colorectal Histology Is Associated With an Increased Risk of Local Failure in Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. , 2015, International journal of radiation oncology, biology, physics.

[8]  E. Van Cutsem,et al.  Pooled analysis of the surgical treatment for colorectal cancer liver metastases. , 2015, Critical reviews in oncology/hematology.

[9]  Jing Li,et al.  Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases. , 2015, Journal of thoracic disease.

[10]  P. Franco,et al.  Stereotactic ablative radiation therapy as first local therapy for lung oligometastases from colorectal cancer: a single-institution cohort study. , 2015, International journal of radiation oncology, biology, physics.

[11]  T. de Baère,et al.  Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  I. Poon,et al.  Predictive factors for local control in primary and metastatic lung tumours after four to five fraction stereotactic ablative body radiotherapy: a single institution's comprehensive experience. , 2014, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  S. Eschrich,et al.  Differences Between Colon Cancer Primaries and Metastases Using a Molecular Assay for Tumor Radiation Sensitivity Suggest Implications for Potential Oligometastatic SBRT Patient Selection. , 2014, International journal of radiation oncology, biology, physics.

[14]  M. Scorsetti,et al.  Stereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach , 2014, BMC Cancer.

[15]  Geoffrey G. Zhang,et al.  Study of 201 non-small cell lung cancer patients given stereotactic ablative radiation therapy shows local control dependence on dose calculation algorithm. , 2014, International journal of radiation oncology, biology, physics.

[16]  T. Treasure,et al.  Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? , 2014, Thorax.

[17]  R. Parks,et al.  Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. , 2013, The Lancet. Oncology.

[18]  H. Blons,et al.  EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients , 2013, Cancer medicine.

[19]  A. Luciani,et al.  Single-center multidisciplinary management of patients with colorectal cancer and resectable synchronous liver metastases improves outcomes. , 2013, Clinics and research in hepatology and gastroenterology.

[20]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[21]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[22]  P. Okunieff,et al.  Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. , 2012, International journal of radiation oncology, biology, physics.

[23]  Hoguen Kim,et al.  The differential impact of microsatellite instability as a marker of prognosis and tumour response between colon cancer and rectal cancer. , 2012, European journal of cancer.

[24]  Roger Berry,et al.  KRAS Mutation Is Associated with Lung Metastasis in Patients with Curatively Resected Colorectal Cancer , 2011, Clinical Cancer Research.

[25]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[26]  T. Lacornerie,et al.  Radiothérapie stéréotaxique robotisée par CyberKnife®: aspects techniques et indications , 2007 .

[27]  P. Radice,et al.  Different Genetic Features Associated with Colon and Rectal Carcinogenesis , 2004, Clinical Cancer Research.

[28]  Quynh-Thu Le,et al.  Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. , 2003, The Annals of thoracic surgery.

[29]  A. McCullough.  Comprehensive molecular characterization of human colon and rectal cancer , 2013 .

[30]  P. Bondiau,et al.  [CyberKnife robotic stereotactic radiotherapy: technical aspects and medical indications]. , 2007, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[31]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.